Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Affimed N.V. AFMD

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority...

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:AFMD)

Fundamentals Snapshot (NDAQ:AFMD)

Current News (NDAQ:AFMD)

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

GlobeNewswire January 9, 2023

Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

GlobeNewswire December 22, 2022

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

GlobeNewswire December 12, 2022

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

GlobeNewswire December 10, 2022

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

GlobeNewswire December 10, 2022

Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting

GlobeNewswire December 1, 2022

Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress

GlobeNewswire November 15, 2022

Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting

GlobeNewswire November 7, 2022

Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022

GlobeNewswire November 4, 2022

Opinion & Analysis (NDAQ:AFMD)

No current opinion is available.

Bullboard Posts (NDAQ:AFMD)